106 research outputs found
Intramolecular and Intermolecular Contributions to the Barriers for Rotation of Methyl Groups in Crystalline Solids: Electronic Structure Calculations and Solid-State NMR Relaxation Measurements
Full text linkBreeding origin and migration pattern of dunlin (Calidris alpina) revealed by mitochondrial DNA analysis
Full text linkDevelopment of 7TM receptor-ligand complex models using ligand-biased, semi-empirical helix-bundle repacking in torsion space: application to the agonist interaction of the human dopamine D2 receptor
Get PDFLinear and Circular Dichroism Studies of π → π* Transitions in Steroidal Dienes and α, β-Unsaturated Ketones
No full text990 Treatment with a combination of mMAb17-1A, GM-CSF, alpha-interferon and 5-fluorouracil of patients with advanced colorectal carcinoma (CRC)
No full textSurvival Benefits of Chemotherapy for Patients with Advanced Pancreatic Cancer in A Clinical Real-World Cohort
No full textClinical outcomes of chemotherapy for patients with advanced pancreatic adenocarcinoma in a real-world setting might differ from outcomes in randomized clinical trials (RCTs). Here we show in a single-institution cohort of 595 patients that median overall survival (OS) of patients who received gemcitabine alone (n = 185; 6.6 months (95% CI; 5.5–7.7)) was the same as in pivotal RCTs. Gemcitabine/capecitabine (n = 60; 10.6 months (95% CI; 7.8–13.3)) and gemcitabine/nab-paclitaxel (n = 66; 9.8 months (95% CI; 7.9–11.8)) resulted in a longer median OS and fluorouracil/oxaliplatin/irinotecan (n = 31, 9.9 months (95% CI; 8.1–11.7)) resulted in a shorter median OS than previously reported. Fluorouracil/oxaliplatin (n = 35, 5.8 months (95% CI; 4.5–7)) and best supportive care (n = 206, 1.8 months (95% CI; 1.5–2.1)) could not be benchmarked against any RCTs. The degree of protocol adherence explained differences between real-world outcomes and the respective RCTs, while exposure to second-line treatments did not
Summary of maximum grade for study related toxicity during treatment cycle number 1.
No full text<p>*Represents the number of subjects (of total n = 12) experiencing adverse event during cycle number 1 with lenalidomide and gemcitabine.</p><p>**Graded using NCI CTCAE V 3.0</p><p>ALAT = Alanine aminotransferase; ASAT = Aspartate aminotransferase</p><p>Summary of maximum grade for study related toxicity during treatment cycle number 1.</p
Treatment exposures, number of treatment cycles and median delivered dose of the study drugs.
No full text<p>*NA = not applicable</p><p>** Administered dose / planned dose according to the protocol per cohort (%)</p><p>*** Median administered dose / planned dose according to the protocol per patient per cohort (%)</p><p>Treatment exposures, number of treatment cycles and median delivered dose of the study drugs.</p
Summary of maximum grade for toxicity (aggregate for all treatment cycles) (NCI CTCAE.V3.0.).
No full text<p>*G = Grade</p><p>**Represents the number of subjects experiencing adverse event with lenalidomide and gemcitabine.</p><p>*** One patient with grade 4 gastrointestinal perforation underwent acute surgery, died postoperatively day 6 in acute respiratory insufficiency.</p><p>Summary of maximum grade for toxicity (aggregate for all treatment cycles) (NCI CTCAE.V3.0.).</p
- …
